After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...
In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...
Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...
One critical aspect is the recent approval of KarXT for schizophrenia, which, although positive, was anticipated and thus unlikely to significantly affect the stock’s value. The drug’s labeling was ...
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback